Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease

Table 4

One-year outcomes.

Study endpoints	Overall population (n = 1198)	Nondiabetic (n = 768)	Diabetic (n = 430)	value
TLF	28 (2.3%)	11 (1.4%)	17 (3.9%)	0.006
TLR	13 (1%)	4 (0.5%)	9 (2%)	0.014
TVMI	4 (0.3%)	1 (0.1%)	3 (0.6%)	0.110
Cardiac death	11 (0.9%)	6 (0.7%)	5 (1.1%)	0.513
MACE	40 (3.3%)	21 (2.7%)	19 (4.4%)	0.120
Myocardial infarction	4 (0.3%)	1 (0.1%)	3 (0.6%)	0.110
TVR	18 (1.5%)	8 (1%)	10 (2.3%)	0.080
All-cause death	18 (1.5%)	12 (1.5%)	6 (1.3%)	0.820
Others
CABG + PCI	56 (4.6%)	33 (4.2%)	23 (5.3%)	0.408
Angiographic follow-up at 12 months
	Overall population (n = 535)	Nondiabetic (n = 349)	Diabetic (n = 186)	value
Reference vessel diameter (mm)	2.5 ± 0.7	2.5 ± 0.8	2.5 ± 0.2	0.629
Minimum lumen diameter before angioplasty (mm)	0.35 ± 1.87	0.39 ± 2.34	0.28 ± 0.23	0.315
Minimum lumen diameter after angioplasty (mm)	2.06 ± 0.35	2.07 ± 2.35	2.04 ± 2.35	0.136
Acute gain	1.79 ± 0.41	1.8 ± 0.41	1.77 ± 0.42	0.154
Minimum lumen diameter 12 months after angioplasty (mm)	1.97 ± 0.44	2 ± 0.39	1.89 ± 0.53	0.007
Late lumen loss (mm)	0.12 ± 0.30	0.09 ± 0.25	0.17 ± 0.37	0.003
Binary restenosis, n (%)	13 (2.4%)	4 (1.1%)	9 (4.8%)	0.008

Statistically significant. CABG: coronary artery bypass graft; MACE: major adverse cardiac events; PCI: percutaneous coronary intervention; TLF: target lesion failure; TLR: target lesion revascularization; TVMI: target vessel myocardial infarction; TVR: target vessel revascularization.